Cytovale Expands Sepsis Detection Technology Access
In an exciting development for hospitals and patients alike, Cytovale, a leading medical diagnostics company, has broadened access to its IntelliSep rapid sepsis detection technology across multiple health facilities. This significant expansion follows the outstanding results seen in early deployments which have showcased remarkable improvements in patient care.
IntelliSep's Impact on Patient Care
The IntelliSep system is celebrated for its role in reducing the risk-adjusted sepsis mortality index by an impressive 30% during its initial rollout. This achievement reflects Cytovale's commitment to pioneering advanced detection methods for critical health challenges, specifically focusing on sepsis—a condition that requires rapid diagnosis and treatment to prevent severe outcomes.
Cytovale's Collaboration with Health Systems
Under the leadership of E.J. Kuiper, President and CEO of the Franciscan Missionaries of Our Lady Health System, this health establishment has become a trailblazer in sepsis diagnostics. They've not only embraced the IntelliSep but have also committed to implementing the technology throughout their emergency departments. "We are excited to be the first health system in the country to integrate this advanced diagnostic tool into our daily operations," Kuiper remarked, highlighting their dedication to innovative healthcare solutions.
Key Achievements since Implementation
Following the adoption of IntelliSep at Our Lady of the Lake Regional Medical Center, significant enhancements in patient outcomes have been documented. These include faster triage times, improved survival rates, and a notable reduction in hospital stays. Specifically, patients identified at risk for sepsis benefited greatly, receiving faster care and spending an average of 1.28 days less in the hospital compared to those who did not utilize the service.
Cost-Effectiveness and Efficiency
In addition to improving health outcomes, the implementation of IntelliSep has also generated substantial cost savings. On average, hospitals have reported savings of $1,429 per patient tested. This efficiency allows healthcare providers to better allocate resources, minimizing unnecessary blood culture tests by approximately 30%, thereby freeing up valuable nursing time to focus more on direct patient care.
Future Directions for Cytovale
Cytovale continues to expand its reach and impact within emergency medicine. By making the IntelliSep technology more widely available, the company is not only improving the detection of sepsis but also establishing new standards for patient-centered care across health systems.
About Cytovale
Cytovale is dedicated to revolutionizing patient care through its innovative diagnostic solutions. The company’s FDA-cleared IntelliSep leverages advanced technologies, including machine learning and microfluidics, to deliver rapid and accurate assessments of immune system responses indicative of sepsis. Based in San Francisco, Cytovale is supported by prominent venture partners and remains at the forefront of medical diagnostics.
Frequently Asked Questions
What is IntelliSep?
IntelliSep is a rapid sepsis detection technology developed by Cytovale, designed to provide quick and accurate diagnostic results in emergency departments.
How does IntelliSep improve patient outcomes?
The technology enables earlier detection of sepsis, leading to faster triage and treatment, ultimately resulting in improved survival rates and shorter hospital stays.
Where is IntelliSep available?
IntelliSep is now available at multiple hospitals within the Franciscan Missionaries of Our Lady Health System and is expanding to more locations.
What are the financial implications of using IntelliSep?
Hospitals utilizing IntelliSep have realized significant cost savings, averaging $1,429 per patient tested, along with reduced utilization of blood cultures.
What is the goal of Cytovale?
Cytovale aims to enhance patient care by pioneering diagnostic tools that enable rapid detection of critical conditions like sepsis, improving overall healthcare outcomes.
